Beclomethasone Dipropionate (Inhaled)
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Maintenance treatment of asthma as prophylactic therapy | Adults and children ≥4 years | Controller monotherapy or with LABA | FDA Approved |
Beclomethasone dipropionate (BDP) is a first-generation inhaled corticosteroid with a unique pharmacological profile as the only ICS prodrug currently marketed for asthma. BDP itself has weak glucocorticoid receptor binding (relative receptor affinity [RRA] = 53 relative to dexamethasone = 100) and is rapidly hydrolysed by pulmonary esterases to its active metabolite, beclomethasone-17-monopropionate (17-BMP), which has high receptor affinity (RRA = 1,345). The current formulation, QVAR RediHaler, uses an HFA-propelled extrafine solution that produces small particles (MMAD ~1 µm), enabling superior small-airway deposition compared with conventional larger-particle ICS formulations. This allows equivalent or superior efficacy at lower nominal doses than the older CFC-BDP products. QVAR RediHaler is the first and only breath-actuated aerosol ICS, eliminating the need for hand-breath coordination required by traditional press-and-breathe MDIs. It requires no priming, no shaking, and no spacer.
Dosing
QVAR RediHaler — Adults & Adolescents ≥12 Years
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Not currently on ICS | 40–80 mcg BID | 40–320 mcg BID | 320 mcg BID | Starting dose based on disease severity Onset within 24 h; max benefit 3–4 weeks |
| Switching from another ICS | 40, 80, 160, or 320 mcg BID | 40–320 mcg BID | 320 mcg BID | Select starting dose based on strength of previous ICS and disease severity If inadequate response after 2 weeks, increase dose |
QVAR RediHaler — Paediatric Patients 4–11 Years
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| All paediatric patients | 40 mcg BID | 40–80 mcg BID | 80 mcg BID | If inadequate response to 40 mcg after 2 weeks, increase to 80 mcg BID Maximum 8 inhalations per day (any strength) |
QVAR RediHaler delivers consistent, dose-proportional systemic exposure: 2 actuations of the 40 mcg strength provide a dose comparable to 1 actuation of the 80 mcg strength. This allows flexible dosing adjustments using either canister strength. Compared with older CFC-BDP products, QVAR’s extrafine HFA formulation achieves comparable or greater efficacy at approximately half the nominal dose, so direct mcg-for-mcg substitution from CFC-BDP is inappropriate.
Pharmacology
Mechanism of Action
Beclomethasone dipropionate is a synthetic halogenated (9α-chloro) glucocorticoid that functions as a prodrug. Upon inhalation, BDP is rapidly hydrolysed by pulmonary esterases to the pharmacologically active metabolite beclomethasone-17-monopropionate (17-BMP). More than 90% of inhaled BDP is found as 17-BMP in the systemic circulation. 17-BMP binds to intracellular glucocorticoid receptors with high affinity, suppressing inflammatory gene transcription and upregulating anti-inflammatory protein synthesis. In the airways, this reduces eosinophilic infiltration, mast cell mediator release, cytokine production, and airway hyperresponsiveness. BDP is chemically related to dexamethasone, differing by a chlorine at C-9 (instead of fluorine) and a 16β-methyl group (instead of 16α).
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Inhaled BDP bioavailability: 2% (parent); 17-BMP systemic bioavailability: 62% (lung + oral combined); ~36% from pulmonary absorption alone. Cmax BDP 88 pg/mL at 0.5 h; Cmax 17-BMP 1,419 pg/mL at 0.7 h (after 320 mcg QVAR) | Extrafine HFA particles (~1 µm MMAD) achieve superior small-airway deposition vs conventional ICS. Negligible oral bioavailability of parent BDP due to near-complete presystemic conversion |
| Distribution | BDP: Vss 20 L; 17-BMP: Vss 424 L; plasma protein binding 87% (17-BMP) | The small Vss of BDP reflects rapid elimination before maximal tissue distribution; 17-BMP distributes extensively into tissues including airways |
| Metabolism | Primary activation: esterase hydrolysis of BDP → 17-BMP (active, RRA 1,345) in lung and plasma; further oxidative metabolism via CYP3A4 to 21-BMP and beclomethasone (BOH), both with low activity. Clearance: BDP 150 L/h; 17-BMP 120 L/h | Key differentiator: primary activation is esterase-mediated (not CYP3A4), so the clinical significance of CYP3A4 inhibitor interactions is less than with fluticasone propionate or budesonide, though downstream CYP3A4 metabolism exists |
| Elimination | Primarily via faeces; <10% excreted in urine. t½ BDP 0.5 h; t½ 17-BMP 2.7–2.8 h (IV data); ~4 h (BAI study) | Rapid clearance of parent compound limits systemic exposure; the active metabolite’s moderate half-life supports twice-daily dosing |
Side Effects
No individual adverse reaction reached ≥10% in the pooled QVAR RediHaler placebo-controlled trials. The FDA PI threshold for reporting was >3% and greater than placebo.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Oral candidiasis | >3% (> placebo) | ICS class effect; dose-dependent; mouth rinsing after each inhalation is essential prevention |
| Upper respiratory tract infection | >3% (> placebo) | High background rate; self-limiting; not necessarily drug-related |
| Nasopharyngitis | >3% (> placebo) | Common across ICS class; typically mild |
| Allergic rhinitis | >3% (> placebo) | May be unmasked or co-existing condition; consider intranasal corticosteroid |
| Oropharyngeal pain | >3% (> placebo) | Local irritation from inhaled steroid; mouth rinsing reduces incidence |
| Sinusitis | >3% (> placebo) | Background rate in asthma patients; assess for allergic component |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Back pain | 1–3% | Likely incidental; not clearly drug-related |
| Influenza | 1–3% | Seasonal background infection rate |
| Viral gastroenteritis | 1–3% | Likely incidental |
| Ear infection | 1–3% | Common in paediatric populations |
| Diarrhoea | 1–3% | May relate to swallowed fraction |
| Myalgia | 1–3% | Typically mild and self-limiting |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| HPA axis suppression / adrenal crisis | Rare (dose-dependent) | Weeks to months at high doses | Cosyntropin stimulation test; carry steroid card during systemic steroid transition; patients on ≥20 mg prednisone equivalent at greatest risk |
| Growth suppression in children | Expected (ICS class effect) | Months | Stadiometry monitoring; use lowest effective dose; HFA-BDP showed ~0.5 cm/year less growth velocity vs CFC-BDP with large-volume spacer in 12-month paediatric study |
| Glaucoma / cataracts | Uncommon (long-term) | Months to years | Ophthalmology referral for visual changes; monitor IOP in patients with risk factors |
| Paradoxical bronchospasm | Very rare | Immediately after inhalation | Rescue SABA; discontinue QVAR RediHaler; switch to alternative ICS |
| Psychiatric/behavioural changes (primarily children) | Rare (postmarketing) | Variable | Aggression, depression, sleep disorders, psychomotor hyperactivity, and suicidal ideation reported; monitor behaviour in paediatric patients; consider discontinuation |
| Anaphylaxis / hypersensitivity | Very rare | Minutes | Discontinue immediately; standard anaphylaxis management; urticaria, angioedema, rash, bronchospasm reported |
Drug Interactions
Beclomethasone dipropionate has a fundamentally different metabolic profile from fluticasone propionate and budesonide. While the primary activation step (BDP → 17-BMP) is mediated by esterases rather than CYP3A4, the QVAR PI notes that subsequent oxidative metabolism of BDP and its metabolites involves CYP3A4-catalysed biotransformation. However, the FDA PI for QVAR RediHaler does not include a specific drug interaction section for CYP3A4 inhibitors, in contrast to fluticasone and budesonide labels which carry explicit CYP3A4 interaction warnings. This makes beclomethasone a potentially preferred ICS in patients requiring strong CYP3A4 inhibitors (e.g., HIV protease inhibitors, azole antifungals).
Monitoring
- Lung FunctionBaseline, 1–4 weeks, then q3–12 months
RoutineFEV1 or PEF to confirm response. Improvement in symptoms can occur within 24 hours; pulmonary function improvement usually apparent within 1–4 weeks. Maximum benefit may take 3–4 weeks. - Growth (Paediatric)Every 6–12 months
RoutineStadiometry in all children on ICS. A 12-month controlled study showed HFA-BDP (100–400 mcg/day) was associated with ~0.5 cm/year less growth velocity vs CFC-BDP with large-volume spacer. Titrate to lowest effective dose. - Oropharyngeal HealthEach visit
RoutineInspect for oral candidiasis. Reinforce mouth rinsing with water (without swallowing) after each inhalation. - HPA AxisIf high-dose ICS or adrenal symptoms
Trigger-basedMorning cortisol or cosyntropin stimulation if using maximum doses chronically or if patient reports fatigue, weakness, hypotension. Essential during transition from systemic corticosteroids. Patients on ≥20 mg/day prednisone equivalent are at greatest risk. - BMD & OcularLong-term high-dose, risk factors
Trigger-basedDEXA for osteoporosis risk factors. Ophthalmology referral for visual changes including blurred vision. Monitor for cataracts and glaucoma (ICS class effect). - Behaviour (Paediatric)Each visit
RoutinePostmarketing reports of aggression, depression, sleep disorders, psychomotor hyperactivity, and suicidal ideation primarily in children. Monitor mood and behaviour changes at each visit. - Inhaler TechniqueEach visit
RoutineBreath-actuated device: open cap → inhale → close cap. No pressing, no shaking, no spacer required. Wipe mouthpiece weekly with dry cloth. Discard when counter reaches 0.
Contraindications & Cautions
Absolute Contraindications
- Primary treatment of status asthmaticus or acute asthma episodes requiring intensive measures
- Hypersensitivity to beclomethasone dipropionate or any ingredient in QVAR RediHaler
Relative Contraindications (Specialist Input Recommended)
- Active pulmonary tuberculosis: Use only with appropriate anti-TB therapy
- Untreated systemic fungal, bacterial, viral, or parasitic infections
- Ocular herpes simplex
Use with Caution
- Patients transferring from systemic corticosteroids: Risk of adrenal insufficiency; taper slowly. Deaths have occurred during transition
- Chickenpox or measles exposure in unimmunised patients: Risk of severe or fatal illness; consider VZIG or IG prophylaxis
- Hepatic impairment: No formal PK studies; use with caution
Deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids to inhaled corticosteroids. Patients previously on 20 mg or more per day of prednisone (or equivalent) are most susceptible. Recovery of HPA function may require several months. During stress, patients should resume oral corticosteroids immediately and contact their physician.
Patient Counselling
Purpose of Therapy
Beclomethasone is a daily controller medication that reduces inflammation in the airways to prevent asthma symptoms and attacks. It does not provide immediate relief during an asthma episode. A rescue inhaler should always be available. Improvement may begin within 24 hours, but full benefit typically takes 3–4 weeks.
How to Use QVAR RediHaler
The QVAR RediHaler is a breath-actuated inhaler — the medication releases automatically when you breathe in. There is no need to press a button, shake the device, or use a spacer. Three simple steps: (1) open the cap, (2) inhale one time through the mouthpiece, (3) close the cap. After each use, rinse your mouth with water and spit. Keep the inhaler clean and dry; never wash it or put any part in water. Wipe the mouthpiece weekly with a clean, dry cloth.
Sources
- QVAR RediHaler (beclomethasone dipropionate HFA) inhalation aerosol prescribing information. Teva Respiratory, LLC. Revised 09/2025. Reference ID: 5666235. FDA Label Primary source for all dosing, Table 1 adverse reaction data, contraindications, warnings, PK summary (Cmax, t½, elimination), and postmarketing safety data.
- QVAR (beclomethasone dipropionate HFA) inhalation aerosol prescribing information (MDI formulation). FDA Label (2017) Source for 12-month paediatric growth study data (HFA-BDP vs CFC-BDP) and additional PK parameters from QVAR MDI studies.
- Daley-Yates PT, Price AC, Sisson JR, et al. Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. Br J Clin Pharmacol. 2001;51(5):400–409. DOI Definitive IV PK study (N=12); source for BDP CL 150 L/h, Vss 20 L, t½ 0.5 h; 17-BMP CL 120 L/h, Vss 424 L, t½ 2.7 h; inhaled BDP bioavailability 2%; 17-BMP 62%; lung absorption 36%.
- Harrison LI, Kurup S, Wagner C, et al. Pharmacokinetics of beclomethasone 17-monopropionate from a beclomethasone dipropionate extrafine aerosol in adults with asthma. Eur J Clin Pharmacol. 2002;58(3):197–201. DOI Dose and strength proportionality study for extrafine BDP aerosol; confirmed t½ of 17-BMP ~2.8 h in asthmatic patients.
- Nonaka T, Nave R, McCracken N, et al. Pharmacokinetics of beclomethasone dipropionate delivered by breath-actuated inhaler and metered-dose inhaler in healthy subjects. J Aerosol Med Pulm Drug Deliv. 2017;30(5):338–348. PubMed BAI vs MDI bioequivalence study (N=72); demonstrated bioequivalence of RediHaler (BAI) to QVAR MDI at 320 mcg; mean 17-BMP t½ ~4 h.
- Hampel FC Jr, Carr W, Gillespie M, Small CJ. Evaluation of beclomethasone dipropionate (80 and 160 micrograms/day) via a breath-actuated inhaler for persistent asthma. Allergy Asthma Proc. 2017;38(6):419–430. DOI Pivotal efficacy trial for QVAR RediHaler; source for the placebo-controlled safety data contributing to Table 1 adverse reactions.
- Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2024 update. GINA Defines low/medium/high dose ICS classifications; recommends beclomethasone as a preferred ICS option when CYP3A4 interactions are a concern.
- Leach CL, Kuehl PJ, Chand R, et al. Characterization of respiratory deposition of fluticasone-salmeterol HFA-134a and HFA-134a beclomethasone in asthmatic patients. J Allergy Clin Immunol. 2009;124(6 Suppl):S84–S87. Lung deposition study demonstrating superior small-airway deposition of extrafine HFA-BDP particles compared with conventional ICS formulations.
- Derendorf H, Nave R, Drollmann A, et al. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J. 2006;28(5):1042–1050. DOI Comparative ICS pharmacokinetics review; BDP prodrug status, receptor binding affinities (BDP RRA 53, 17-BMP RRA 1,345), and esterase-mediated activation discussed.